These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15701778)

  • 1. Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial.
    Naritoku DK; Hulihan JF; Schwarzman LK; Kamin M; Olson WH
    Ann Pharmacother; 2005 Mar; 39(3):418-23. PubMed ID: 15701778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topiramate titration to response: analysis of individualized therapy study (TRAITS).
    Dodson WE; Kamin M; Kraut L; Olson WH; Wu SC
    Ann Pharmacother; 2003 May; 37(5):615-20. PubMed ID: 12708932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group.
    Privitera M; Fincham R; Penry J; Reife R; Kramer L; Pledger G; Karim R
    Neurology; 1996 Jun; 46(6):1678-83. PubMed ID: 8649569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topiramate in add-on therapy: results from an open-label, observational study.
    Krakow K; Lengler U; Rettig K; Schreiner A; Schauble B;
    Seizure; 2007 Oct; 16(7):593-600. PubMed ID: 17543544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pooled analysis of adjunctive topiramate in refractory partial epilepsy.
    Peeters K; Adriaenssen I; Wapenaar R; Neto W; Pledger G
    Acta Neurol Scand; 2003 Jul; 108(1):9-15. PubMed ID: 12807387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group.
    Faught E; Wilder BJ; Ramsay RE; Reife RA; Kramer LD; Pledger GW; Karim RM
    Neurology; 1996 Jun; 46(6):1684-90. PubMed ID: 8649570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of adjunctive topiramate in infants (1-24 months) with refractory partial-onset seizures: a randomized, multicenter, open-label phase 1 study.
    Manitpisitkul P; Shalayda K; Todd M; Wang SS; Ness S; Ford L
    Epilepsia; 2013 Jan; 54(1):156-64. PubMed ID: 23157581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
    Contin M; Riva R; Albani F; Avoni P; Baruzzi A
    Ther Drug Monit; 2002 Jun; 24(3):332-7. PubMed ID: 12021622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topiramate: a review of its use in the treatment of epilepsy.
    Lyseng-Williamson KA; Yang LP
    Drugs; 2007; 67(15):2231-56. PubMed ID: 17927286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting.
    Guerrini R; Carpay J; Groselj J; van Oene J; Schreiner A; Lahaye M; Schwalen S;
    Seizure; 2005 Sep; 14(6):371-80. PubMed ID: 15961326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy.
    Arroyo S; Dodson WE; Privitera MD; Glauser TA; Naritoku DK; Dlugos DJ; Wang S; Schwabe SK; Twyman RE;
    Acta Neurol Scand; 2005 Oct; 112(4):214-22. PubMed ID: 16146489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from valproic acid onto topiramate in adolescents and adults with epilepsy.
    Schreiner A; Stollhoff K; Ossig W; Unkelbach S; Lüer W; Bogdanow M; Schauble B;
    Acta Neurol Scand; 2009 May; 119(5):304-12. PubMed ID: 19133865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topiramate in the long-term management of refractory epilepsy. Topiramate YOL Study Group.
    Abou-Khalil B
    Epilepsia; 2000; 41(S1):72-6. PubMed ID: 10768305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose topiramate in adults with treatment-resistant partial-onset seizures.
    Guberman A; Neto W; Gassmann-Mayer C;
    Acta Neurol Scand; 2002 Oct; 106(4):183-9. PubMed ID: 12225311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topiramate: a new antiepileptic drug.
    Privitera MD
    Ann Pharmacother; 1997 Oct; 31(10):1164-73. PubMed ID: 9337443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study.
    Hottinger A; Sutter R; Marsch S; Rüegg S
    CNS Drugs; 2012 Sep; 26(9):761-72. PubMed ID: 22823481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postmarketing experience with topiramate and cognition.
    Tatum WO; French JA; Faught E; Morris GL; Liporace J; Kanner A; Goff SL; Winters L; Fix A;
    Epilepsia; 2001 Sep; 42(9):1134-40. PubMed ID: 11580760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topiramate slow dose titration: improved efficacy and tolerability.
    Albsoul-Younes AM; Salem HA; Ajlouni SF; Al-Safi SA
    Pediatr Neurol; 2004 Nov; 31(5):349-52. PubMed ID: 15519117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of topiramate pharmacokinetics and tolerability in children with epilepsy.
    Rosenfeld WE; Doose DR; Walker SA; Baldassarre JS; Reife RA
    Pediatr Neurol; 1999 May; 20(5):339-44. PubMed ID: 10371378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison.
    Levisohn PM; Holland KD
    Epilepsy Behav; 2007 Jun; 10(4):547-52. PubMed ID: 17482520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.